We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ferri–Liposomes: Preformulation and Selective Cytotoxicity against A549 Lung Cancer Cells.
- Authors
de Souza, Marina Guedes Fonseca; de Jesus Guedes, Fabrícia Nunes; Tebaldi, Marli Luiza; do Nascimento Alencar, Éverton; Amaral-Machado, Lucas; do Egito, Eryvaldo Sócrates Tabosa; de Barros, André Luis Branco; Soares, Daniel Crístian Ferreira; Pastorino, Fabio; Dosio, Franco
- Abstract
Liposomes have become successful nanostructured systems used in clinical practices. These vesicles are able to carry important drug loadings with noteworthy stability. The aim of this work was to develop iron oxide-loaded stealth liposomes as a prospective alternative for the treatment of lung cancer. In this study, citric acid iron oxide nanoparticles (IONPs-Ac) were synthesized and encapsulated in stealth liposomes. Their cytotoxicity and selectivity against lung tumor cells were assessed. Stealth liposomal vesicles, with relevant content of IONPs-Ac, named ferri–liposomes (SL-IONPs-Ac), were produced with an average size of 200 nm. They displayed important cytotoxicity in a human lung cancer cells model (A549 cells), even at low concentrations, whereas free IONPs-Ac displayed adequate biocompatibility. Nevertheless, the treatment at the same concentration of ferri–liposomes against HEK-293 cells, a normal human cell lineage, was not significantly cytotoxic, revealing a probable lung tumor selectiveness of the fabricated formulation. Furthermore, from the flow cytometry studies, it was possible to infer that ferri–liposomes were able to induce A549 tumor cells death through apoptosis/ferroptosis processes, evidenced by a significant reduction of the mitochondrial membrane potential.
- Subjects
LIPOSOMES; CANCER cells; LUNG cancer; IRON oxide nanoparticles; ALTERNATIVE treatment for cancer; MITOCHONDRIAL membranes
- Publication
Pharmaceutics, 2021, Vol 13, Issue 5, p712
- ISSN
1999-4923
- Publication type
Article
- DOI
10.3390/pharmaceutics13050712